Cryoviva Life Sciences | Stem Cell Preservation Service

Fibromyalgia, which is a disorder of widespread pain, fatigue, and cognitive difficulties, affects millions of individuals around the globe. It is highly prevalent, but its exact cause remains unknown. Available therapies manage only the symptoms, not the underlying cause. But with recent advances in regenerative medicine, fibromyalgia has been successfully treated using stem cell therapy in a novel manner. Understanding Fibromyalgia Fibromyalgia is a widespread musculoskeletal pain with associated fatigue, sleep disturbance, and impaired memory. Fibromyalgia is believed to be the result of a change in the brain and spinal cord's reaction to pain messages. Fibromyalgia does not cause inflammation or tissue damage, unlike some other rheumatic diseases, so it is very difficult to diagnose and cure flawlessly.  How Stem Cells Can Help Stem cells are unique in that they can differentiate into more than one cell type and possess regenerative capability as well. In fibromyalgia, the spot...

In the rapidly evolving landscape of modern medicine, stem cell therapies stand at the forefront of innovation, offering hope for treating a wide array of previously intractable conditions. At Cryoviva Life Sciences, we're dedicated to advancing the field of stem cell therapies, providing cutting-edge solutions that harness the regenerative power of these remarkable cells. Understanding Stem Cell Therapies Stem cell therapies involve using stem cells or their derivatives to repair damaged tissues and treat diseases. These versatile cells have the unique ability to develop into various cell types, making them powerful tools in regenerative medicine. Types of Stem Cell Therapies At Cryoviva Life Sciences, we work with several types of stem cells for therapeutic applications: Hematopoietic Stem Cells: Used in treating blood disorders and certain cancers. Mesenchymal Stem Cells: Effective in addressing inflammatory and autoimmune conditions. Neural Stem Cells: Promising for treating...